At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Pre-Mkt 04-13 07:54:39 EDT
0.9168
+0.1828
+24.90%
盘前0.8641
-0.0527-5.75%
07:28 EDT
High0.9688Low0.7341Vol1.48M
Open0.7609D1 Closing0.7340Amplitude31.98%
Mkt Cap10.50MTradable Cap8.88MTotal Shares11.45M
T/O1.32MT/O Rate15.30%Tradable Shares9.68M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)
TIPRANKS  ·  04-07
Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)
Aprea Therapeutics closes oversubscribed private placement raising $30 million gross proceeds
Reuters  ·  04-01
Aprea Therapeutics closes oversubscribed private placement raising $30 million gross proceeds
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
THOMSON REUTERS  ·  04-01
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $1.2 From $4
THOMSON REUTERS  ·  03-31
Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $1.2 From $4
BRIEF-Aprea Therapeutics Highlights Positive Emerging Clinical Activity For Wee1 Inhibitor, Apr-1051
Reuters  ·  03-30
BRIEF-Aprea Therapeutics Highlights Positive Emerging Clinical Activity For Wee1 Inhibitor, Apr-1051
Aprea Therapeutics announces oversubscribed private placement raising about $30 million
Reuters  ·  03-30
Aprea Therapeutics announces oversubscribed private placement raising about $30 million
Aprea reports confirmed partial response for APR-1051 in Phase 1 ACESOT-1051 trial
Reuters  ·  03-30
Aprea reports confirmed partial response for APR-1051 in Phase 1 ACESOT-1051 trial
Aprea Therapeutics Inc - Expects Offering Proceeds to Extend Cash Runway Into Q1 2028
THOMSON REUTERS  ·  03-30
Aprea Therapeutics Inc - Expects Offering Proceeds to Extend Cash Runway Into Q1 2028
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
THOMSON REUTERS  ·  03-30
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for Wee1 Inhibitor, Apr-1051, With a Confirmed Partial Response in the Ongoing Phase 1 Acesot-1051 Trial
THOMSON REUTERS  ·  03-30
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for Wee1 Inhibitor, Apr-1051, With a Confirmed Partial Response in the Ongoing Phase 1 Acesot-1051 Trial
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
TIPRANKS  ·  03-17
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
THOMSON REUTERS  ·  03-16
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
TIPRANKS  ·  02-20
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051
Reuters  ·  02-18
BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051
Aprea Therapeutics announces additional clinical activity for APR-1051
TIPRANKS  ·  02-18
Aprea Therapeutics announces additional clinical activity for APR-1051
Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial
Reuters  ·  02-18
Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial
Aprea Therapeutics Inc - Update From Trial Is Expected in Q2 of 2026
THOMSON REUTERS  ·  02-18
Aprea Therapeutics Inc - Update From Trial Is Expected in Q2 of 2026
Aprea Therapeutics Inc - Tumor Shrinkage of 50% and Significant CA-125 Biomarker Reduction Observed at 220 Mg Dose Level
THOMSON REUTERS  ·  02-18
Aprea Therapeutics Inc - Tumor Shrinkage of 50% and Significant CA-125 Biomarker Reduction Observed at 220 Mg Dose Level
Aprea Therapeutics Announces Additional Positive Clinical Activity for Wee1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing Acesot-1051 Trial
THOMSON REUTERS  ·  02-18
Aprea Therapeutics Announces Additional Positive Clinical Activity for Wee1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing Acesot-1051 Trial
BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics
Reuters  ·  02-12
BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics

Introduction

Company Name.
Aprea Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Issue price:
--